Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31091209 | 1.00 | PDE10A (0.39) | PDE10A | |
| SCHEMBL10846996 | 0.88 | PDE10A (0.31) | PDE10A | |
| SCHEMBL16577352 | 0.88 | PDE10A (0.36) | PDE10A | |
| SCHEMBL10847567 | 0.86 | ALDH1A1 (0.35) | PDE10A | |
| SCHEMBL10036942 | 0.85 | PDE10A (0.31) | PDE10A | |
| SCHEMBL25153045 | 0.82 | PDE10A (0.46) | PDE10A | |
| SCHEMBL23499459 | 0.77 | — | — | |
| SCHEMBL30973457 | 0.77 | — | — | |
| SCHEMBL25311759 | 0.75 | PDE10A (0.47) | PDE10A | |
| SCHEMBL10966321 | 0.72 | GOT1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655287-A2 | INHIBITORS OF NLRP3 | MWYNGIL THERAPEUTICS, INC. (US) | 2025-12-03 | — | — | EP | disclosed |
| WO-2024158941-A2 | INHIBITORS OF NLRP3 | MWYNGIL THERAPEUTICS, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| EP-2599774-B1 | CONDENSED PYRIDINE COMPOUNDS AS CB2 CANNABINOID RECEPTOR LIGANDS | ASTELLAS PHARMA INC (JP) | 2016-07-06 | — | — | EP | disclosed |
| US-9309231-B2 | Bridged ring compounds as hepatitis C virus (HCV) inhibitors and pharmaceutical applications thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-04-12 | — | — | US | disclosed |
| US-9309231-B2 | Bridged ring compounds as hepatitis C virus (HCV) inhibitors and pharmaceutical applications thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-04-12 | — | — | US | disclosed |
| US-20150079028-A1 | Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2015-03-19 | — | — | US | disclosed |
| US-20150079028-A1 | Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2015-03-19 | — | — | US | disclosed |
| US-8791106-B2 | Fused ring pyridine compound | ASTELLAS PHARMA INC. (JP) | 2014-07-29 | — | — | US | disclosed |
| WO-2014082381-A1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-06-05 | — | — | WO | disclosed |
| WO-2014019344-A1 | BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND PHARMACEUTICAL APPLICATIONS THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-02-06 | — | — | WO | disclosed |
| US-8629143-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20130143874-A1 | FUSED RING PYRIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-06-06 | — | — | US | disclosed |
| EP-2599774-A1 | CONDENSED RING PYRIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2013-06-05 | — | — | EP | disclosed |
| EP-2504317-A1 | POTASSIUM CHANNEL MODULATORS | Abbott Laboratories (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011066168-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-06-03 | — | — | WO | disclosed |
| US-20110124642-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143874-A1 | FUSED RING PYRIDINE COMPOUND | CNR2, CNR1, TRPV1 | PDE10A 3142/4885 |
| US-20110124642-A1 | POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNQ2, KCNQ3 | PDE10A 1423/4885 |
| US-20150079028-A1 | Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof | SLC10A1, HAVCR2, UGT1A3 | PDE10A 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.